Omalizumab for the Treatment of Chronic Spontaneous Urticaria: Association Between Body Mass Index and Outcome

INTRODUCTION: Omalizumab has been recently registered as a third-line therapy for chronic spontaneous urticaria. OBJECTIVES: In this study, we aimed to provide real life data by reporting our experience with omalizumab in the treatment of chronic spontaneous urticaria. METHODS: A retrospective data...

Descripción completa

Detalles Bibliográficos
Autores principales: Russo, Irene, Cazzolla, Sara, Pampaloni, Francesca, Alaibac, Mauro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Mattioli 1885 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9681238/
https://www.ncbi.nlm.nih.gov/pubmed/36534565
http://dx.doi.org/10.5826/dpc.1204a148

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9681238/
https://www.ncbi.nlm.nih.gov/pubmed/36534565
http://dx.doi.org/10.5826/dpc.1204a148

Ejemplares similares